Ganglioside G_Q1b Monoclonal Antibody (Clone CGM3) - Purified IgM

Ganglioside G_Q1b is a sialic acid-containing glycosphingolipid that has been found in myelin of the oculomotor nerves and dorsal root ganglia, as well as neuromuscular spindle fibers.^1,2 It is found on the plasma membrane, where it is anchored by the ceramide moiety with the sialylated oligosaccharide on the extracellular side.² In axonal myelin, it helps to stabilize the paranodal region in the node of Ranvier.¹ Ganglioside G_Q1b is similar in shape to lipo-oligosaccharides (LOS) on the membrane of certain pathogens, including the bacterium C. jejuni. Due to this similarity, autoantibodies against ganglioside G_Q1b can be formed during infection with C. jejuni. Ganglioside G_Q1b monoclonal antibody (CGM3) induces muscle fiber twitching then paralysis in ex vivo mouse phrenic nerve hemidiaphragm preparations from mice passively immunized with ganglioside G_Q1b monoclonal antibody (CGM3) but only when human serum is present to provide complement and not when applied alone.² Autoantibodies against ganglioside GQ1b are found in the cerebrospinal fluid in a majority of patients during the acute phase of Miller-Fisher syndrome, a rare variant of Guillain-Barré syndrome characterized by eye movement abnormalities, impaired coordination, and tendon reflex loss.^2,3,1 Cayman’s Ganglioside G_Q1b Monoclonal Antibody (Clone CGM3) - Purified can be used for ELISA, immunofluorescence (IF), and thin-layer chromatography (TLC) applications.

WARNING This product is not for human or veterinary use.

1. Noioso, C.M., Bevilacqua, L., Acerra, G.M., et al. Miller Fisher syndrome: An updated narrative review. Front. Neurol. 14, 1250774 (2023).

2. Goodyear, C.S., O'Hanlon, G.M., Plomp, J.J., et al. Monoclonal antibodies raised against Guillain-Barré syndrome-associated Campylobacter jejuni lipopolysaccharides react with neuronal gangliosides and paralyze muscle-nerve preparations. J. Clin. Invest. 104(6), 697-708 (1999).

3. Halstead, S.K., Humphreys, P.D., Goodfellow, J.A., et al. Complement inhibition abrogates nerve terminal injury in Miller Fisher syndrome. Ann. Neurol. 58(2), 203-210 (2005).